BRIEF—Fotivda added to ESMO practice guidelines

UK and USA-based company EUSA Pharma has announced that Fotivda (tivozanib) has been included in the new European Society of Medical Oncology (ESMO) clinical practice guidelines for renal cell carcinoma (RCC).

ESMO has included the therapy as a first-line treatment recommendation for advanced RCC (aRCC) clear cell histology patients.

The guidelines have also recommend Fotivda as a treatment standard for good (or favorable) risk patients and a treatment option for intermediate risk patients.